End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17

Richard Pebody, Fiona Warburton, Joanna Ellis, Nick Andrews, Alison Potts, Simon Cottrell, Arlene Reynolds, Rory Gunson, Catherine Thompson, Monica Galiano, Chris Robertson, Naomh Gallagher, Mary Sinnathamby, Ivelina Yonova, Ana Correa, Catherine Moore, Muhammad Sartaj, Simon de Lusignan, Jim McMenamin, Maria Zambon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction The United Kingdom is in the fourth season of introducing a universal childhood influenza vaccine programme. The 2016/17 season saw early influenza A(H3N2) virus circulation with care home outbreaks and increased excess mortality particularly in those 65 years or older. Virus characterisation data indicated emergence of genetic clusters within the A(H3N2) 3C.2a group which the 2016/17 vaccine strain belonged to. Methods: The test-negative case-control (TNCC) design was used to estimate vaccine effectiveness (VE) against laboratory confirmed influenza in primary care. Results: Adjusted end-of-season vaccine effectiveness (aVE) estimates were 39.8% (95% confidence interval (CI): 23.1 to 52.8) against all influenza and 40.6% (95% CI: 19.0 to 56.3) in 18-64-year-olds, but no significant aVE in ≥ 65-year-olds. aVE was 65.8% (95% CI: 30.3 to 83.2) for 2-17-year-olds receiving quadrivalent live attenuated influenza vaccine. Discussion: The findings continue to provide support for the ongoing roll-out of the paediatric vaccine programme, with a need for ongoing evaluation. The importance of effective interventions to protect the ≥ 65-year-olds remains.

LanguageEnglish
JournalEurosurveillance
Volume22
Issue number44
DOIs
Publication statusPublished - 2 Nov 2017

Fingerprint

Influenza Vaccines
Vaccines
Confidence Intervals
Human Influenza
H3N2 Subtype Influenza A Virus
Attenuated Vaccines
Influenza A virus
Home Care Services
Disease Outbreaks
Primary Health Care
Pediatrics
Viruses
Mortality
United Kingdom

Keywords

  • adolescent
  • adult
  • aged
  • aged, 80 and over
  • case-control studies
  • child
  • child, preschool
  • disease outbreaks
  • female
  • humans
  • immunization programs
  • infant
  • influenza A virus
  • influenza B virus
  • influenza Vaccines
  • influenza, human
  • male
  • middle aged
  • outcome assessment (health care)
  • population surveillance
  • primary health care
  • reverse transcriptase polymerase chain reaction
  • sensitivity and specificity
  • sentinel surveillance
  • United Kingdom
  • vaccination
  • vaccine potency
  • vaccines, attenuated
  • young adult

Cite this

Pebody, R., Warburton, F., Ellis, J., Andrews, N., Potts, A., Cottrell, S., ... Zambon, M. (2017). End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. Eurosurveillance, 22(44). https://doi.org/10.2807/1560-7917.ES.2017.22.44.17-00306
Pebody, Richard ; Warburton, Fiona ; Ellis, Joanna ; Andrews, Nick ; Potts, Alison ; Cottrell, Simon ; Reynolds, Arlene ; Gunson, Rory ; Thompson, Catherine ; Galiano, Monica ; Robertson, Chris ; Gallagher, Naomh ; Sinnathamby, Mary ; Yonova, Ivelina ; Correa, Ana ; Moore, Catherine ; Sartaj, Muhammad ; de Lusignan, Simon ; McMenamin, Jim ; Zambon, Maria. / End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. In: Eurosurveillance. 2017 ; Vol. 22, No. 44.
@article{c31ec11bb2f34951bd0d7bcfa6f9dfbb,
title = "End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17",
abstract = "Introduction The United Kingdom is in the fourth season of introducing a universal childhood influenza vaccine programme. The 2016/17 season saw early influenza A(H3N2) virus circulation with care home outbreaks and increased excess mortality particularly in those 65 years or older. Virus characterisation data indicated emergence of genetic clusters within the A(H3N2) 3C.2a group which the 2016/17 vaccine strain belonged to. Methods: The test-negative case-control (TNCC) design was used to estimate vaccine effectiveness (VE) against laboratory confirmed influenza in primary care. Results: Adjusted end-of-season vaccine effectiveness (aVE) estimates were 39.8{\%} (95{\%} confidence interval (CI): 23.1 to 52.8) against all influenza and 40.6{\%} (95{\%} CI: 19.0 to 56.3) in 18-64-year-olds, but no significant aVE in ≥ 65-year-olds. aVE was 65.8{\%} (95{\%} CI: 30.3 to 83.2) for 2-17-year-olds receiving quadrivalent live attenuated influenza vaccine. Discussion: The findings continue to provide support for the ongoing roll-out of the paediatric vaccine programme, with a need for ongoing evaluation. The importance of effective interventions to protect the ≥ 65-year-olds remains.",
keywords = "adolescent, adult, aged, aged, 80 and over, case-control studies, child, child, preschool, disease outbreaks, female, humans, immunization programs, infant, influenza A virus, influenza B virus, influenza Vaccines, influenza, human, male , middle aged, outcome assessment (health care), population surveillance, primary health care, reverse transcriptase polymerase chain reaction, sensitivity and specificity, sentinel surveillance, United Kingdom, vaccination, vaccine potency, vaccines, attenuated, young adult",
author = "Richard Pebody and Fiona Warburton and Joanna Ellis and Nick Andrews and Alison Potts and Simon Cottrell and Arlene Reynolds and Rory Gunson and Catherine Thompson and Monica Galiano and Chris Robertson and Naomh Gallagher and Mary Sinnathamby and Ivelina Yonova and Ana Correa and Catherine Moore and Muhammad Sartaj and {de Lusignan}, Simon and Jim McMenamin and Maria Zambon",
year = "2017",
month = "11",
day = "2",
doi = "10.2807/1560-7917.ES.2017.22.44.17-00306",
language = "English",
volume = "22",
journal = "Eurosurveillance",
issn = "1560-7917",
number = "44",

}

Pebody, R, Warburton, F, Ellis, J, Andrews, N, Potts, A, Cottrell, S, Reynolds, A, Gunson, R, Thompson, C, Galiano, M, Robertson, C, Gallagher, N, Sinnathamby, M, Yonova, I, Correa, A, Moore, C, Sartaj, M, de Lusignan, S, McMenamin, J & Zambon, M 2017, 'End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17' Eurosurveillance, vol. 22, no. 44. https://doi.org/10.2807/1560-7917.ES.2017.22.44.17-00306

End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. / Pebody, Richard; Warburton, Fiona; Ellis, Joanna; Andrews, Nick; Potts, Alison; Cottrell, Simon; Reynolds, Arlene; Gunson, Rory; Thompson, Catherine; Galiano, Monica; Robertson, Chris; Gallagher, Naomh; Sinnathamby, Mary; Yonova, Ivelina; Correa, Ana; Moore, Catherine; Sartaj, Muhammad; de Lusignan, Simon; McMenamin, Jim; Zambon, Maria.

In: Eurosurveillance, Vol. 22, No. 44, 02.11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17

AU - Pebody, Richard

AU - Warburton, Fiona

AU - Ellis, Joanna

AU - Andrews, Nick

AU - Potts, Alison

AU - Cottrell, Simon

AU - Reynolds, Arlene

AU - Gunson, Rory

AU - Thompson, Catherine

AU - Galiano, Monica

AU - Robertson, Chris

AU - Gallagher, Naomh

AU - Sinnathamby, Mary

AU - Yonova, Ivelina

AU - Correa, Ana

AU - Moore, Catherine

AU - Sartaj, Muhammad

AU - de Lusignan, Simon

AU - McMenamin, Jim

AU - Zambon, Maria

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Introduction The United Kingdom is in the fourth season of introducing a universal childhood influenza vaccine programme. The 2016/17 season saw early influenza A(H3N2) virus circulation with care home outbreaks and increased excess mortality particularly in those 65 years or older. Virus characterisation data indicated emergence of genetic clusters within the A(H3N2) 3C.2a group which the 2016/17 vaccine strain belonged to. Methods: The test-negative case-control (TNCC) design was used to estimate vaccine effectiveness (VE) against laboratory confirmed influenza in primary care. Results: Adjusted end-of-season vaccine effectiveness (aVE) estimates were 39.8% (95% confidence interval (CI): 23.1 to 52.8) against all influenza and 40.6% (95% CI: 19.0 to 56.3) in 18-64-year-olds, but no significant aVE in ≥ 65-year-olds. aVE was 65.8% (95% CI: 30.3 to 83.2) for 2-17-year-olds receiving quadrivalent live attenuated influenza vaccine. Discussion: The findings continue to provide support for the ongoing roll-out of the paediatric vaccine programme, with a need for ongoing evaluation. The importance of effective interventions to protect the ≥ 65-year-olds remains.

AB - Introduction The United Kingdom is in the fourth season of introducing a universal childhood influenza vaccine programme. The 2016/17 season saw early influenza A(H3N2) virus circulation with care home outbreaks and increased excess mortality particularly in those 65 years or older. Virus characterisation data indicated emergence of genetic clusters within the A(H3N2) 3C.2a group which the 2016/17 vaccine strain belonged to. Methods: The test-negative case-control (TNCC) design was used to estimate vaccine effectiveness (VE) against laboratory confirmed influenza in primary care. Results: Adjusted end-of-season vaccine effectiveness (aVE) estimates were 39.8% (95% confidence interval (CI): 23.1 to 52.8) against all influenza and 40.6% (95% CI: 19.0 to 56.3) in 18-64-year-olds, but no significant aVE in ≥ 65-year-olds. aVE was 65.8% (95% CI: 30.3 to 83.2) for 2-17-year-olds receiving quadrivalent live attenuated influenza vaccine. Discussion: The findings continue to provide support for the ongoing roll-out of the paediatric vaccine programme, with a need for ongoing evaluation. The importance of effective interventions to protect the ≥ 65-year-olds remains.

KW - adolescent

KW - adult

KW - aged

KW - aged, 80 and over

KW - case-control studies

KW - child

KW - child, preschool

KW - disease outbreaks

KW - female

KW - humans

KW - immunization programs

KW - infant

KW - influenza A virus

KW - influenza B virus

KW - influenza Vaccines

KW - influenza, human

KW - male

KW - middle aged

KW - outcome assessment (health care)

KW - population surveillance

KW - primary health care

KW - reverse transcriptase polymerase chain reaction

KW - sensitivity and specificity

KW - sentinel surveillance

KW - United Kingdom

KW - vaccination

KW - vaccine potency

KW - vaccines, attenuated

KW - young adult

U2 - 10.2807/1560-7917.ES.2017.22.44.17-00306

DO - 10.2807/1560-7917.ES.2017.22.44.17-00306

M3 - Article

VL - 22

JO - Eurosurveillance

T2 - Eurosurveillance

JF - Eurosurveillance

SN - 1560-7917

IS - 44

ER -